Perspective Therapeutics (FRA:AAJ0) Research & Development: €78.34 Mil (TTM As of Mar. 2026)


FRA:AAJ0 Perspective Therapeutics Inc FRA:AAJ0
31 GF Score
Price €2.56
! 1 Warning Sign
View Full Analysis

What is Perspective Therapeutics Research & Development?

Perspective Therapeutics FRA:AAJ0 +3.72% 31 Research & Development is €78.34 Mil as of Mar. 2026. GuruFocus rates FRA:AAJ0 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Perspective Therapeutics's Research & Development for the three months ended in Mar. 2026 was €18.49 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €78.34 Mil.

Perspective Therapeutics  (FRA:AAJ0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Perspective Therapeutics Research & Development Related Terms

Perspective Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics Research & Development Chart

Perspective Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.18 2.44 19.54 39.76 71.92

Perspective Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.26 14.41 17.33 28.12 18.49
FRA:AAJ0
31GF Score
Perspective Therapeutics Inc FRA:AAJ0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €78.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €78.34 Mil mean?
Perspective Therapeutics (FRA:AAJ0) has a Research & Development of €78.34 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Perspective Therapeutics and its competitors.
Is Perspective Therapeutics' Research & Development too high?
Perspective Therapeutics' current Research & Development is €78.34 Mil. Overall, Perspective Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Research & Development compare to LAB and KIDS?
Perspective Therapeutics' Research & Development of €78.34 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Perspective Therapeutics and its competitors. Perspective Therapeutics's current Research & Development is €78.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (FRA:AAJ0) has a current Research & Development of €78.34 Mil. The current Research & Development is €78.34 Mil. Perspective Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Perspective Therapeutics (FRA:AAJ0), the current Research & Development is €78.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges CATX:USA
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
31GF Score

Get the complete analysis for FRA:AAJ0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.56
Price